anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Long-term antiviral treatment is necessary for chronic hepatitis B (CHB) patients, and treatment safety is imperative for these patients. Previous studies showed tenofovir alafenamide (TAF) has shown efficacy non-inferior to that of tenofovir disoproxil fumarate (TDF) with improved renal and bone safety. However, there is still a lack of a rapid and convenient method to identify CHB patients at high risk of osteoporosis before initiating antiviral treatment. The International Osteoporosis Foundation (IOF) recommended a one-minute osteoporosis risk test to identify early high-risk patients. Our aim was to evaluate the feasibility of the one-minute osteoporosis risk test, along with evaluating the effectiveness and safety for virologically suppressed CHB patients switching to TAF.
METHODS: In this multicenter, prospective study, patients with chronic HBV infection who had been receiving TDF or Entecavir (ETV) for 48 weeks or more with HBV DNA less than 20 IU/mL for longer than 6 months were screened by one-minute osteoporosis risk test. Patients with a high risk of osteoporosis and then diagnosed with osteopenia or osteoporosis by dual-energy X-ray absorptiometry (DEXA) were enrolled. Safety in bone and bone turnover markers and antiviral efficacy of TAF were assessed respectively at 24 and 48 weeks.
RESULTS: 84.95% (175/206) CHB patients screened by one-minute osteoporosis risk test were at risk of osteoporosis.85.71% (150/175) were diagnosed with osteopenia by DEXA. The analysis included a total of 138 patients, of whom 92(62.3%) were male and 46 (37.7%) were female, with a mean age of 45 years old. HBV DNA was suppressed at 48 weeks at 88% (35/40) in the prior ETV group and 90% (88/98) at 48 weeks group in the prior TDF group. Bone mineral density (BMD) of the lumbar spine (L1-L4) from TDF switching to TAF was improved at 24 weeks (1.03±0.11 vs. 0.97±0.12, P = .001) than baseline. Propeptides of type I procollagen (PINP) and beta-C-terminal telopeptides of type 1 collagen (CTX) in serum at 24 weeks after switching from TDF to TAF declined compared with baseline (50.35±18.90 vs. 63.65±19.17, P = .016 and 0.21±0.13 vs. 0.32±0.10, P = .017). BMD, PINP, and CTX in ETV to TAF group remained stable during treatment.
CONCLUSION: Attention should be paid to osteoporosis risk during lone-term nucleot(s)ide analogue treatment. One minute test of osteoporosis risk could rapidly identify most CHB patients at risk of osteoporosis. Given its convenience, we recommend using this test for early screening in CHB patients prior to initiating antiviral treatment. Our results further demonstrated that an improvement in bone safety after switching to TAF in virologically suppressed CHB patients with osteoporosis.
The invention relates to a multilayer transdermal drug delivery system containing ibuprofen structural analogs, which comprises a transdermal patch containing ibuprofen structural analogs and a second combined layer. The transdermal patch comprises a polymer matrix layer, wherein the polymer matrix layer comprises an active ingredient, a compound containing at least one amino group and a pressure-sensitive adhesive. All or part of the active ingredient-amino compound salt and all or part of the free active ingredient formed in the polymer matrix layer are kept in a uniform dissolved state in the polymer matrix, and can be stably stored without recrystallization before use. The transdermal drug delivery system can continuously and controllably deliver ibuprofen structural analogs with therapeutic effect doses within 12-24 hours without transdermal enhancers. The transdermal drug delivery device has excellent wearing capacity, and avoids cold flow phenomenon. Methods of making and using transdermal drug delivery systems are provided.
A snakehead oral liquid uses snakehead as main raw material, and is produced through enzymolysis and alkali treating, mixing sugar and essence to obtain the nutrimental health-care medicine. The prepn process includes:decomposing the fish gruel with enzyme at proper temp. and treating it with alkali to get the protein hydrolysis liq., after coarse filtrating and fine filtrating to get supernatant liq.; mixing proper amt. of simple sugar and spice with the supernatant liq. to obtain the oral liq.. The snakehead oral liquid has rich nutrition good healing function after operation and wound, and also can slow up senility, enhance memory and increase energy etc.
In most experimental protocols, false starts are produced on dry bones obtained through a maceration process for anthropological analyses, for the sake of reproducibility. Although this allows for controlled experimental conditions, the absence of soft parts when experimentally creating false starts does not correspond to the real conditions of criminal dismemberment. The main objective of this study was to determine if the results of experimental work on the characteristics of false starts were valid under medico-legal conditions. In this experimental study, a hand saw (rip saw, wavy set, TPI 32) was used. 240 false starts were produced on human and pig bones. Randomly, the false starts were either produced on a dry bone or on a flesh bone. The criteria for microscopic analysis included the shape of the walls, the shape and visibility of striae on the floor, the shape of the profile, and the minimum width of the false start. On human bone, 100% of the false starts produced on a bone that had previously undergone a maceration process for anthropological analyses (dry bone) allowed the definition of all the blade characteristics. This was the case for 78.3% on bone in the presence of soft tissue (flesh bone). The striae on the floor of the false start are in some cases less visible with flesh bones, implying that it may be more difficult to conclude on the characteristics of a saw under medico-legal conditions.
Microparticle based amplification (MBA) for high sensitivity and high speed analyte detection is described. MBA is based on signal amplification achieved by use of a signal amplification microparticle that contains a plurality of signaling molecules attached to a plurality of positions on the surface of the microparticle, in combination with a plurality of analyte binding molecules attached to a plurality of positions on the surface. Each signaling molecule in turn has a plurality of signal emitting moieties, such as acridinium, attached thereto. This is combined with a separating microparticle such as a ferromagnetic particle, also having an analyte binding molecule attached to the surface so that a complex comprising the analyte, the signal amplification microparticle and the separating microparticle is formed. The complex emits a signal that is amplified many fold relative to the stoichemetric amount of analyte molecules in the sample. Particular embodiments include methods for detecting bacteria, antigens, antibodies and nucleic acids.
PURPOSE:To obtain the titled substance useful as a synthetic intermediate for photographic spectroscopic sensitizing dyestuff and analgesic and anti-inflammatory agent, etc. in high yield at a low cost, by reacting a urea derivative with a malonic acid derivative in the presence of a carbodiimide derivative under mild conditions. CONSTITUTION:A urea derivative of formula II (R<1> and R<2> are H, alkyl, aralkyl or aryl, etc.) is reacted with a malonic acid derivative of formula III (R<3> is H, alkyl, aralkyl or aryl) in the presence of a carbodiimide derivative of formula IV(R is alkyl or aryl) to give a compound of formula I . Acetonitrile, acetone and ethyl acetate, etc. are preferred as a reaction solvent, and the reaction temperature is preferably 20-40 deg.C. The raw material compound of formula IIis preferably dissolved in the reaction solvent after once warming in the reaction.
Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
The use of concomitant cisplatin-based chemo-radiation for cervical cancer has improved survival of locally advanced cervical cancer patients and has become the standard of care. A meta-analysis revealed that the addition of concurrent chemotherapy to radiation increased the 5-year overall survival rate by 6% (HR 0.81: 60 vs 66%), and 5-year disease-free survival rate by 8%, though there is still considerable need for improvement as most patients who relapse are incurable. The unmet need is particularly higher in patients that are at high risk of recurrence. The main negative prognostic factors are higher FIGO stage as well as the presence of positive lymph nodes. Current studies are evaluating role of adjuvant chemotherapy following chemo-radiation in locally advanced disease and will possibly improve survival by reducing risk of distant metastases, however at the cost of excessive toxicity.

PARP inhibitors have shown considerable clinical benefit especially in platinum-sensitive relapsed ovarian cancer. Several PARP inhibitors have been evaluated in other gynaecological malignancies and three PARP inhibitors (olaparib, rucaparib \& niraparib) are approved by European Medicines Agency and Food \& Drug Administration for treatment or as maintenance therapy in ovarian cancer. Human papillomavirus causes oxidative stress that may result in DNA single-strand breaks. In cervical cancer PARP-1 expression/activity may be up-regulated in response to the ongoing oxidative stress (HPV and inflammation), and this may promote progression. This may create a vicious circle of inflammation, PARP activation, NAD+ consumption, adenosine triphosphate consumption, necrosis, and inflammation. PARPi may limit the role of PARP-1 in promoting inflammation and oxidative stress. There is theoretical plausibility that PARPi may have a role in the treatment of cervical carcinoma.

This phase II randomized placebo-controlled double-blind study will evaluate the efficacy and safety of rucaparib as adjuvant treatment for patients with locally advanced cervical cancer who are responding to chemo-radiation. This investigator-initiated study will be performed within the GCIG/ENGOT collaboration
The steroid enzyme 5α-reductase is responsible for the conversion of testosterone to the more-potent androgen dihydrotestosterone (DHT). The catalytic cleavage of nucleic acid encoding 5α-reductase by a ribozyme which selectively recognizes such nucleic acid reduces the level of expression of 5α-reductase by mammalian cells including human cells treated with such ribozyme. The reduction of nucleic acid (e.g. mRNA) levels leads to a corresponding reduction of enzyme levels and dihydrotestosterone levels in surrounding tissues, thus providing a therapeutic effect. The transformation of 5α-reductase producing cells with an expression vector containing a structural gene for a ribozyme is shown to decrease 5α-reductase expression. Pharmaceutical compositions and methods useful for topically administering effective amounts of such a ribozyme to hair follicle cells also are exemplified.
PROBLEM TO BE SOLVED: To provide a method for controlling the proliferation of carcinoma cells through a paternally expressed gene 10 (PEG10). SOLUTION: The PEG10 protein is proved to inhibit apoptosis and promote the proliferation of the carcinoma cells. The PEG10 protein is found to be degraded through interaction with an SIAH1 protein. The method for controlling the cell proliferation and apoptosis through the PEG10 protein is provided. Furthermore, a new method for screening an anticancer agent utilizes the PEG10 protein. The induction of the apoptosis with the carcinoma cells as a specific target can be carried out by the screening to develop a drug inhibiting the cell proliferation. Since the PEG10 protein is specifically expressed in hepatomatous cells, the PEG10 protein is an ideal target molecule for diagnosis and treatment of hepatocarcinoma.
The invention discloses a compound capable of inhibiting beta-secretase, and a preparation method and application thereof. The structure of the compound is shown in a formula I, formula II or formula III as described in the specification. In the formula I, X is S or NH; R1 is selected from hydrogen and nitro group; R2 and R4 are same or different and independently selected from the group consisting of hydrogen, halogen, nitro group and substituted aryl group; R3 is selected from the group consisting of hydrogen, nitro group, straight-chain and branched-chain alkyl and substituted alkyl groups with a carbon number of 1 to 4, alkylamino or alkyloxy group with a carbon number of 1 to 4 and alkylamido group with a carbon number of 1 to 4; R is located at position 2, 3 or 4 of a benzene ring and selected from the group consisting of hydrogen, straight-chain and branched-chain alkyl and substituted alkyl groups with a carbon number of 1 to 4, alkylamino or alkyloxy group with a carbon number of 1 to 4 and alkylamido group with a carbon number of 1 to 4. In the formula II, R is selected from different substituted aryl groups. In the formula III, R is selected from hydrogen or cyano group. Experiments prove that the compound provided by the invention has good beta-secretase inhibitory activity and has wide application values as a beta-secretase inhibitor.
PROBLEM TO BE SOLVED: To obtain a urea-containing component useful as an agent for treating hair by forming a clathrate compound of urea used as a moisture retaining agent for the skin using a specific compound. SOLUTION: This urea-containing component is obtained by forming a clathrate compound of urea using a fatty acid and/or a fatty acid compound. For example, when a fatty acid ethyl ester is used, a mixture of the ester and urea is boiled to reflux in a non-oxidative atmosphere, especially in nitrogen atmosphere together with urea dissolved in ethanol until the urea in the mixture is dissolved, the mixture is cooled, finally to not higher than 10 deg.C, and formed precipitates are collected by filtration. It is preferable that a polyunsaturated fatty acid is partially used as the fatty acid. Especially, ω-3-fatty acid is preferable. Since the ω-3-fatty acid can prevent inflammation, the obtained agent is suitable as a medical ointment.
FIELD: veterinary microbiology. SUBSTANCE: only toxic strains of Escherichia coli were used for anatoxin preparing. After 5-7 days culturing on Hottinger medium toxin is separated from microbial mass by filtration through sterilizing plates. Toxin is inactivated in filtrate with formalin (final concentration is 0.3-0.4%) followed by exposition at 37 C for 10-12 days. Obtained anatoxin is precipitated with 10% aluminopotassium alum solution (as measured 1% for total volume). Complex anatoxin is mixed at equal ratio with antigen obtained from E. coli strains broth cultures grown at 37 C for 2 days by microbial mass washing off with saline solution containing 0.3-0.4% formalin. Microbe cells count is brought about to concentration 50-60 billion and hydrogen peroxide is added to washing off up to concentration 0.15-0,25%. Mixture of anatoxin and antigen is diluted with sterile distilled water up to concentration 5 billion microbe bodies. EFFECT: high antitoxic and antimicrobial expressing immunity of vaccine prepared.
The neuroinflammatory response to intracortical microelectrodes (IMEs) used with brain-machine interfacing (BMI) applications is regarded as the primary contributor to poor chronic performance. Recent developments in high-plex gene expression technologies have allowed for an evolution in the investigation of individual proteins or genes to be able to identify specific pathways of upregulated genes that may contribute to the neuroinflammatory response. Several key pathways that are upregulated following IME implantation are involved with the complement system. The complement system is part of the innate immune system involved in recognizing and eliminating pathogens - a significant contributor to the foreign body response against biomaterials. Specifically, we have identified Complement 3 (C3) as a gene of interest because it is the intersection of several key complement pathways. In this study, we investigated the role of C3 in the IME inflammatory response by comparing the neuroinflammatory gene expression at the microelectrode implant site between C3 knockout (C3-/-) and wild-type (WT) mice. We have found that, like in WT mice, implantation of intracortical microelectrodes in C3-/- mice yields a dramatic increase in the neuroinflammatory gene expression at all post-surgery time points investigated. However, compared to WT mice, C3 depletion showed reduced expression of many neuroinflammatory genes pre-surgery and 4 weeks post-surgery. Conversely, depletion of C3 increased the expression of many neuroinflammatory genes at 8 weeks and 16 weeks post-surgery, compared to WT mice. Our results suggest that C3 depletion may be a promising therapeutic target for acute, but not chronic, relief of the neuroinflammatory response to IME implantation. Additional compensatory targets may also be required for comprehensive long-term reduction of the neuroinflammatory response for improved intracortical microelectrode performance.
This study aimed to recruit 150 patients with knee osteoarthritis from the hospital outpatient department. Random coding was generated using a computer network-based random system, and the subjects will be divided into five groups: real acupuncture, non-acupuncture at real-acupoint, shallow acupuncture at real-acupoint, shallow acupuncture at non-meridian and non-acupoint, and waiting treatment group in a 1:1:1:1 ratio. Acupuncture sessions were conducted three times a week for two weeks. Patients in the waiting treatment group did not receive acupuncture therapy during the study period but received acupuncture treatment after the trial. Outcome measures included Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) score, Visual Analogue Pain (VAS) score, Massachusetts General Hospital Acupuncture Sensation Scale (MASS) needle sensation score, and blind evaluation scale. Data collection occurred at baseline, one week, and two weeks.
At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
1483502 Denture cleanser COLGATEPALMOLIVE CO 6 Aug 1974 [9 Aug 1973] 12960/77 Divided out of 1483501 Heading C5D A solid denture cleanser which on mixing with water effervesces and dissolves in the water to form a solution for soaking dentures, the denture comprising substantially anhydrous trisodium phosphate, a water-soluble monopersulphate to react with the trisodium phosphate to cause effervescence with liberation of oxygen bubbles, which inhibits the tendency of the phosphate to form slowly soluble lumps on admixture with the water, the phosphate being present in an amount such that the solution has a pH of at least 9, and a chlorine compound which liberates hypochlorite chlorine in contact with water, present in an amount so as to provide at least 100 p.p.m. of active chlorine in the solution after effervescence has ceased. The chlorine compound may be sodium or potassium dichloroisocyanurate. The cleanser may be in powder or tablet form, and may include two dyes, both of which are bleached by the solution, but one being more rapidly bleached than the other, thus providing a colour change at a chosen time after the cleanser has been mixed with water. Surfactants such as sodium lauryl sulphate may be present to promote foaming. Binders, lubricants and disintegrants may be present in the tablets, and solid polyethylene oxide may be present in the tablets or granular compositions. The disintegrant may be hydrolysed cereal solids.
The first 45 patients will be monitored but the results will not be displayed. The second half of the patients the oximeter will have their monitoring data available online in the ward.
Five percent of children have at least one UTI episode and 30% of these episodes recur. Recurrences and the risk of renal damage are indications for long term antimicrobial prophylaxis, but emerging antimicrobial resistance underlines the need for alternatives. The bacteria causing urinary tract infection arise from the stools. Dietary changes can alter the balance of faecal bacteria. Vaccinium berries and products containing lactobacilli have been shown to act against the coliform bacteria that cause most urinary tract infections. In our previous study cranberry juice was effective in preventing symptomatic recurrences of urinary tract infections in women. The objective of our study is to determine whether recurrences of urinary tract infection in children can be prevented with cranberry juice.
Dose-dependent reductions in absolute forced expiratory volume over 1 second (FEV1) were observed in MAYZENT-treated patients as early as 3 months after treatment initiation. In a placebo-controlled trial in adult patients, the decline in absolute FEV1 from baseline compared to placebo was 88 mL [95% confidence interval (CI): 139, 37] at 2 years. The mean difference between MAYZENT-treated patients and patients receiving placebo in percent predicted FEV1 at 2 years was 2.8% (95% CI: -4.5, -1.0). There is insufficient information to determine the reversibility of the decrease in FEV1 after drug discontinuation. In Study 1, five patients discontinued MAYZENT because of decreases in pulmonary function testing. MAYZENT has been tested in MS patients with mild to moderate asthma and chronic obstructive pulmonary disease. The changes in FEV1 were similar in this subgroup compared with the overall population. Spirometric evaluation of respiratory function should be performed during therapy with MAYZENT if clinically indicated.
The present invention relates to paste for treating the disease symptoms of arthritis and hyperosteogeny. The tincture is prepared from the Chinese herbal medicine of red sage root, suberect spatholobus, clematis root, doubleteeth pubesscent angelica root, safflower, cape jasmine fruit, pepper, etc. through the processes of selection, pulverization, mixing, alcohol extraction, filtration, concentration and substrate preparation. Through clinical observation, the paste of the present invention has an obvious therapeutic effect on treating rheumatic arthritis, rheumatoid arthritis, etc., and the total effective rate reaches 98%. Through conventional blood and urine detection before treatment and after treatment, the tincture does not have any adverse reaction. Thus, the tincture is safe externally applied medicine.
Biologically active PDGF analogs expressed in eucaryotic cells are disclosed.  The analogs are produced by eucaryotic cells transformed with a DNA construct comprising a strong transcriptional promoter directing the expression of a gene which encodes a protein having substantially the same biological activity as PDGF. Suitable genes include the v-sis gene or a derivative of the v-sis gene of simian sarcoma virus or portions thereof, or the human cDNA gene for PDGF or portions thereof.  In particular, DNA sequences encoding polypeptides substantially homologous to the B chain of PDGF are preferred.  A secretory signal sequence may be provided upstream of the gene, enabling secretion of the gene product from the host cell.  Mitogenic activity is one of the biological activities possessed by these PDGF analogs, making them useful in promoting the growth of mammalian cells.